The Takeda zasocitinib FDA review will proceed under the agency’s priority pathway after regulators accepted the company’s New Drug Application. Takeda Pharmaceutical (NYSE: TAK) is seeking approval for adults with moderate-to-severe plaque psoriasis.
Zasocitinib is an investigational oral tyrosine kinase 2 inhibitor, commonly described as a TYK2 inhibitor. Takeda said the candidate demonstrated skin clearance in Phase 3 plaque psoriasis studies supporting the application.
Takeda Zasocitinib FDA Review Advances Oral Psoriasis Candidate
Priority review shortens the FDA’s target review period for therapies that may offer meaningful improvements over available treatments. The designation accelerates regulatory evaluation but does not indicate that approval is certain or that the agency has reached a conclusion on benefits and risks.
Takeda provides regulatory and clinical updates through its official newsroom. A complete assessment will depend on the Phase 3 efficacy data, adverse-event profile, manufacturing information and any questions raised during the review.
The Takeda zasocitinib FDA review creates a potential near-term catalyst for the company’s immunology portfolio. If approved, the drug would enter a competitive psoriasis market containing injectable biologics and other oral therapies, making comparative efficacy, safety and convenience important to adoption.
